The Certara Blog

Author: Masoud Jamei

Dr. Jamei is the Vice President of Research and Development at Simcyp (a Certara company) where he works with a team of 30 scientists and 10 programmers focusing on design, development and implementation of various aspects of systems pharmacology including in vitro-in vivo extrapolation techniques, physiologically-based PK/PD models of small and large molecules and applying top-down PopPK data analysis to PBPK models in healthy volunteer and patient populations. He has been the author or co-author of over 50 manuscripts and book chapters and 90 abstracts in the field of modelling and biosimulation. He has also been an invited speaker and a session organiser/moderator at national and international meetings and also leads well-known Simcyp hands-on workshops on model-based drug development. He currently serves as a vice-chair of the BPS Special Interest Group on PK/PD and Systems Pharmacology and a steering committee member of the AAPS Systems Pharmacology Focus Group. In 2002 he earned a PhD in Control Systems Engineering at the University of Sheffield, UK and carried out one year of post-doctoral research there. In 2003 he joined Simcyp and he is a visiting Senior Lecturer at the Manchester Pharmacy School, UK since 2011.

Recent Posts

Banish hERGphobia - Using Systems Pharmacology to Assess Cardiac Safety

Banish hERGphobia: Using Systems Pharmacology to Assess Cardiac Safety

Is the era of “hERGphobia” finally coming to an end? Drug-induced cardiovascular adverse events are one of the leading causes of drug withdrawals from the market and of drug label restrictions. As a result, biopharmaceutical companies are keen to identify new drug candidates with a propensity to cause arrhythmias, or the heart to beat with […]

Read More
Personalized Toxicology - A New Paradigm for Chemical Risk Assessment

Personalized Toxicology: A New Paradigm for Chemical Risk Assessment

Historically, toxicity testing has been conducted by giving lab animals high doses of chemicals and observing them for adverse events. But quantifying the risks chemicals pose to humans based on animal studies is problematic as the chemical doses are often orders of magnitude higher than environmental levels. Moreover, this process is slow, expensive, and ethically […]

Read More